.png){kind=icon}
.png){kind=icon}
Return
Treatment of breast cancer brain metastases in the era of novel drugs
.png){kind=icon}
PRE
AI
J
G
E
G
A
DOI：10.1016/j.ctrv.2026.103179.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• BCBMs are an increasing clinical challenge, driven by longer survival and improved detection of CNS involvement. • Systemic therapies with intracranial activity are reshaping BCBM management, complementing or delaying local treatments. • Targeted agents and ADCs improved outcomes in the HER2+ disease, and new options are emerging for HR+/HER2− and TNBC. • Broader inclusion of patients with CNS disease in clinical trials is essential to treatment strategies for BCBMs.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers